Results 111 to 120 of about 23,963,911 (309)

PB2626: THROMBOPOIETIN RECEPTOR AGONISTS FOR RESISTANT THROMBOCYTOPENIA IN PREGNANCY A CASE SERIES AND REVIEW OF LITERATURE

HemaSphere, 2023
Gamal Sayed, Sarah Elkourashy, Dina Soliman, Naela Al Mallahi, Awni Alshurafa, Amna Gamil, Firyal Ibrahim, Mohammed Alnajjar, Shehab Mohamed   +8 more
doaj   +1 more source

Outcomes and toxicities after proton partial breast radiotherapy for early stage, hormone receptor positive breast cancer: 3-Year results of a phase II multi-center trial. [PDF]

Clin Transl Radiat Oncol, 2022
Choi JI, Prabhu K, Hartsell WF, DeWees T, Sinesi C, Vargas C, Benda RK, Cahlon O, Chang AL.   +8 more
europepmc   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

FEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang, Ruslana Romaniuk, Hristo L. Svilenov   +2 more
wiley   +1 more source

Cancer Trends: Childhood cancer

, 2017
This is the second trends report NCRI has published on childhood cancers, updating a previous report covering 1994-20111. To facilitate summary of the amount and complexity of material included, presentation and layout has been in general retained from ...
National Cancer Registry Ireland (NCRI)
core  

Immune checkpoint inhibitor-related myocarditis during DUO-E regimen for endometrial cancer: The first case report in gynecologic oncology

Gynecologic Oncology Reports
Background: Immune checkpoint inhibitors (ICIs) are increasingly used in gynecologic oncology, with the DUO-E regimen—carboplatin, paclitaxel, and durvalumab—recently approved in Japan for advanced or recurrent endometrial cancer.
Eri Yamabe, Hironori Yamamoto, Keita Asano, Taku Yasui, Masashi Fujita, Tsuyoshi Hisa, Miho Kitai   +6 more
doaj   +1 more source

Liver organoids: modelling complexity in homeostasis and disease

FEBS Letters, EarlyView.
Studying liver in vitro has been challenging because simple 2D cell cultures fail to capture liver's cellular and architectural complexity. To bridge this gap, scientists increasingly use organoids, 3D liver models which better mimic liver composition and function. This review examines recent advances in liver organoid complexity and realism, discusses
Anna M. Dowbaj, Meritxell Huch
wiley   +1 more source

Cancer Trends: Primary Liver Cancer

, 2016
During 2012-2014, a little over half (58%) of all primary liver cancers were histologically confirmed, 37% were diagnosed radiologically only via x-ray, MRI/CT scan etc. and 5% did not have a method of diagnosis specified.
National Cancer Registry Ireland (NCRI)
core  

Associations between immune checkpoint inhibitor response, immune-related adverse events, and steroid use in RADIOHEAD: a prospective pan-tumor cohort study

Journal for ImmunoTherapy of Cancer
Background Immune checkpoint inhibitors (ICIs) have led to enduring responses in subsets of patients with cancer. However, these responses carry the risk of immune-related adverse events (irAEs), which can diminish the overall benefit of ICI treatment ...
Lisa H Butterfield, John E Connolly, Nicholas L Bayless, Jeffrey A Bluestone, Samantha Bucktrout, Aik Choon Tan, Kevan C Herold, Zoe Quandt, Anastasia Lucas, Arabella Young, Christine N Spencer, Lacey J Padron, Samantha I Liang, EnJun Yang, Samantha Stone, Muhammad Zaki Hidayatullah Fadlullah, Sara Siebel Marr, Marshall A Thompson, Mark S Anderson   +18 more
doaj   +1 more source

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. [PDF]

ESMO Open, 2022
Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, Hochmair MJ, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Musso E, Havel L, Bondarenko I, Losonczy G, Conev N, Mann H, Dalvi TB, Jiang H, Goldman JW.   +20 more
europepmc   +1 more source

Epigenetic reprogramming of lineage switching in cancer

FEBS Letters, EarlyView.
Cancer cells rarely commit to a single identity. Epigenetic mechanisms and tumor microenvironment cues push epithelial cells toward flexible, hybrid states that can shift into mesenchymal, neuroendocrine, or stem‐like fates, driving metastasis, drug resistance, and tumor heterogeneity. Targeting the epigenetic regulators behind these transitions, using
Ezgi Boyvatlı, Burcu Akman, Ezgi Bağırsakçı, Nese Atabey, Serap Erkek‐Ozhan   +4 more
wiley   +1 more source